Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.60 7.50 7.70 7.60 7.50 7.60 42,389 08:00:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.2 -2.1 - 21

Evgen Pharma Share Discussion Threads

Showing 7876 to 7896 of 8400 messages
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
DateSubjectAuthorDiscuss
22/3/2021
11:59
OK thanks - I'll go and do more research..
ptolemy
22/3/2021
11:58
There's a 28 day assessment on each patient following the 14 days of dosing, that's why the DSMB were able to assess the first 60 patients recruited to the trial, and prelimanary efficacy data will be available for the first 100 during Q2...Gl ;-) Background to the Trial 1 STAR-COVID 19 TRIAL TRAINING BACKGROUND AND OVERVIEW Community-acquired pneumonia is a leading cause of morbidity and mortality in the UK There have been no new therapies for managing pneumonia since advent of antibiotics in 1950s The global pandemic caused by novel coronavirus SARS-CoV-2, has highlighted the need for new drugs to treat pneumonia Development of anti-inflammatory therapies that prevent late stage complications is needed Such therapies are likely to be efficacious for a range of acute respiratory infections, including COVID-19 Patients with pneumonia and suspectedCOVID-19 are eligible for this trial. Patients do not require a positive COVID-19 test to be eligible .................... Background to the Trial 2 The nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) is part of the human natural defence against inflammatory and oxidative stress such as the inflammation that occurs during a severe viral infection In animal studies, pharmacological activation of Nrf2 reduces the severity of acute respiratory distress syndrome (ARDS) SFX-01(stabilised sulforaphane), a drug developed by EvgenPharma, is an activator of Nrf2 SFX-01 has been tested in over 130 subjects in clinical trials and is well tolerated with main side effects being GI related and ameliorated by taking after food In this study one 300mg capsule of SFX-01 is taken orally per day for 14 days This is the first study of the effect of SFX-01 in humans with acute respiratory infections at risk of developing ARDS ....................... The trial will test the following hypothesis: Treatment with SFX-01 in addition to standard care will be superior to placebo plus standard care in achieving improved clinical status in patients initially hospitalized with community acquired pneumonia (including patients investigated for suspected COVID19 infection). ......................... Primary objective: To evaluate the clinical efficacy of SFX-01 compared to placebo on top of standard care in adult patients initially hospitalized with community acquired pneumonia.Outcome measure:7 point ordinal scale measured on Day 15. Secondary Objectives: Evaluate the clinical efficacy of SFX-01 relative to standard care in adult patients hospitalized with suspected COVID-19 Evaluate the safety of the intervention through 28 days of follow-up as compared to the control arm Outcome measures: Cumulative incidence of serious Adverse events (SAEs) Discontinuation or temporary suspension of treatment .............................. Exploratory objectives (All sites) Biofire analysis of nasal swab or sputum sample Subanalysis of outcomes according to the causative pathogen Exploratory objectives (TAYSIDE ONLY) Analysis of Nrf2 pathway activity in isolated peripheral blood mononuclear cells Neutrophil functional studies in isolated cells Measurement of interleukin-6, interleukin-1 beta and TNF-alpha in blood hTtps://star-covid19.com/
moneymunch
22/3/2021
11:54
>If the trial last 28 days/per person it must be over for the first 100 recruits? Yes, hence why they can do a preliminary assessment. The STAR-COVID trial is for treatment of ARDS (Acute respiratory distress syndrome), either caused by COVID-19 or other causes.
on target
22/3/2021
11:50
On Target, I thought Sulforaphane is for treatment of chronic illness? (I've been taking it for nearly 10-years.) If the trial last 28 days/per person it must be over for the first 100 recruits?
ptolemy
22/3/2021
11:48
Ptolemy, Prof Chalmers will announce preliminary efficacy data from SFX-01's Covid/Ards patient trials, as highlighted by ontarget....Q2 is early as next month and positive data confirming or suggesting efficacy will be a game changer imho. We're now at a point where multiple news is expected from across the pipeline, hence my view that “newsflow is likely to come thick and fast from now on in” , starting with todays news of the appointment of a Chief Buisness Officer, and much more to expected in the coming days and weeks. Gl ;-)
moneymunch
22/3/2021
11:23
"THEN at least a year of dosing" - no, dosing takes place over a 14 day period followed by another 14 days of assessment.
on target
22/3/2021
11:21
On the STAR trial see this RNS ptolemy: https://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-Update-on-Data-Safety-Review-ST/84549909 "Following this positive step, the next event in the trial involves an assessment of safety and futility by the DMC of unblinded data on the first 100 patients treated. In addition to the DMC safety and futility assessment, Dundee University has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in-patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during Q2 of the calendar year 2021. " So as well as the DMC safety and futility assessment we will be getting a preliminary assessment of efficacy.
on target
22/3/2021
11:16
Moneymunch / Anyone “newsflow is likely to come thick and fast from now on in” May I ask what’s behind this view? What EVG have said is: “initial data will be available during the second quarter of calendar 2021”. That’s initial data for safety only. That’s like saying ‘the trial has shown water is safe to drink’ They’ve also said, “Completion of recruitment to the STAR trial is anticipated at the end of 2021 /Q1 2022, assuming there are no substantial changes in the total patients to be recruited.” So, 9 more months of recruitment, THEN at least a year of dosing. Randomised controlled trials take a long time. In the interim we can't expect positive news (that can only come at the end of the trial). So, by default any interim news must be neutral/negative. Any views why these ideas are wrong is welcomed.
ptolemy
22/3/2021
09:26
A positive start is always a good omen early in Spring.
clocktower
22/3/2021
08:12
(Stay) classy amaretto 🤦🏼‍♂️
bumpa33
22/3/2021
07:44
grovel harder.
bumpa33
22/3/2021
07:42
Morning all, sorry for thick question but how does the Guild coin work please? I asked Nobby for a coin a while back... do I need to do anything?! TIA.
raldo
22/3/2021
07:23
She's not being taken on for nothing ... that's for sure !
amaretto1
22/3/2021
07:21
Good, good - one would hope she’ll have plenty of ‘business̵7; to preside over - soon!
bumpa33
22/3/2021
07:02
RNS Number : 9197S Evgen Pharma PLC 22 March 2021 Evgen Pharma Plc ("Evgen" or "the Company") Appointment of Chief Business Officer Evgen (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer, inflammation and acute respiratory distress syndrome, announces that Helen Kuhlman PhD will be joining the Company as Chief Business Officer effective from 1 April 2021. Dr Kuhlman has over 20 years' experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies. She joins Evgen from the Development Bank of Wales where she was responsible for equity investment in technology companies and for managing investments in the bank's portfolio companies. Prior to that Helen was Vice-President of Corporate Development at Chronos Therapeutics Ltd and was previously at Innovate UK where she created and delivered the £180m Biomedical Catalyst competitive grant scheme funded by the UK government. Dr Kuhlman holds a PhD in physiology and pharmacology from the University of Leicester, UK. Dr Huw Jones CEO of Evgen commented: "We are delighted to appoint Helen to a key senior role within the Company as we increase our focus on potential partnering activities for SFX-01. Helen will also have a key role within the team in providing a commercial focus on our indication selection, horizon scanning and competitor intelligence activities."
moneymunch
21/3/2021
15:02
The link for GWP was more a general example of an ‘end result’ of what can happen when there’s a fundamental step change in view for a substance that was once seen as ‘just’ an illegal recreational drug. We’re still ‘just’ a cruciferous vegetable to 99.9% of the population.
bumpa33
21/3/2021
11:58
I wonder if the planned IND for SFX-01 in the US is related to Prof Thu Le's ongoing work and evaluation of SFX-01 for CKD at University of Rochester, New York....now that would be big news imho....Gla ;-) February 2020 Professor Le and colleagues have previously published research showing an association between CKD patients with the GSTM1 null allele and more rapid CKD progression, and also that consumption of cruciferous vegetables (a source of sulforaphane) is associated with lower risks of kidney failure, with stronger effects in those having the GSTM1 null allele. On this basis, Professor Le approached Evgen, the developer of SFX-01, a stable form of sulforaphane that has demonstrated excellent safety and tolerability in previous clinical trials. Thu Le, Professor of Medicine, and Chief of the Division of Nephrology at the University of Rochester Medical Center said: "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing." htTps://uk.advfn.com/stock-market/london/evgen-pharma-EVG/share-news/Evgen-Pharma-PLC-University-of-Rochester-Collabora/81743058 .................... January 2021 Eat Your Broccoli: Oxidative Stress, NRF2, and Sulforaphane in Chronic Kidney Disease January 2021 Nutrients 13(1):266 DOI: 10.3390/nu13010266 Authors: Scott Liebman University of Rochester Thu H Le University of Rochester Medical Center Abstract and Figures The mainstay of therapy for chronic kidney disease is control of blood pressure and proteinuria through the use of angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) that were introduced more than 20 years ago. Yet, many chronic kidney disease (CKD) patients still progress to end-stage kidney diseaseĆ¢€”the ultimate in failed prevention. While increased oxidative stress is a major molecular underpinning of CKD progression, no treatment modality specifically targeting oxidative stress has been established clinically. Here, we review the influence of oxidative stress in CKD, and discuss regarding the role of the Nrf2 pathway in kidney disease from studies using genetic and pharmacologic approaches in animal models and clinical trials. We will then focus on the promising therapeutic potential of sulforaphane, an isothiocyanate derived from cruciferous vegetables that has garnered significant attention over the past decade for its potent Nrf2-activating effect, and implications for precision medicine. hTtps://www.researchgate.net/publication/348623288_Eat_Your_Broccoli_Oxidative_Stress_NRF2_and_Sulforaphane_in_Chronic_Kidney_Disease ........................... January 2020 University of Rochester Thu H Le University of Rochester Medical Center GSTM1 Deletion Exaggerates Kidney Injury in Experimental Mouse Models and Confers the Protective Effect of Cruciferous Vegetables in Mice and Humans Significance Statement GSTM1 encodes a member of a superfamily of antioxidant enzymes, and a highly prevalent GSTM1 deletion variant is associated with kidney disease progression in two human study cohorts. In this study, the authors demonstrate that Gstm1 knockout mice exhibit increased oxidative stress, kidney injury, and inflammation in models of CKD and hypertension, and that Gstm1 loss in the parenchyma but not in bone marrow–derived cells drives renal inflammation. Importantly, consumption of broccoli powder or cruciferous vegetables was protective against kidney disease only in Gstm1 knockout mice, and was observed mainly in the human participants in the Atherosclerosis Risk in Communities Study who were homozygous for GSTM1 deletion. These findings suggest that targeting antioxidant therapy specifically in individuals carrying the GSTM1 deletion variant may be effective in delaying kidney disease progression. hTtps://jasn.asnjournals.org/content/31/1/102
moneymunch
21/3/2021
11:46
Evgen have been around a while too, and i wouldn't be surprised if a Nasdaq listing is in the planning in the not too distant, if data confirms the likelihood of efficacy in any of their disease targets, as well as the current work to file an IND for SFX-01 in the US, which we're awaiting news on detail etc. Gl ;-) History Evgen Pharma was founded in 2007 by two venture capital investors. In 2010, the decision was taken to focus on intellectual property secured under licence from PharmAgra Labs Inc, a US chemical synthesis company that had discovered a method for synthesising and stabilising sulforaphane in a sugar lattice. The company branded the stabilised sulforaphane technology, SulforadexĀ®, and began building its pharmaceutical development capability. Evgen Pharma joined the AIM market of the London Stock Exchange in October 2015 and subsequently acquired the world-wide rights to a series of novel sulforaphane analogues from the Spanish Research Council and the University of Seville. In March 2019, Evgen Pharma announced positive results from the open-label Phase II trial of SFX-01 in patients with oestrogen-positive metastatic breast cancer that had become resistant to all prior lines of hormone therapy. Evgen announced a collaboration with the University of Dundee on the STAR trial in June 2020, investigating whether SFX-01 can reduce the severity, or prevent the onset of, acute respiratory distress syndrome (“ARDS”) in respiratory diseases such as COVID-19. This is a 300-patient randomised, controlled trial. In September 2020 Evgen announced a licence agreement with Juvenescence for SFX-01 in non-pharmaceutical applications for high-end nutritional health products. JuvLife is a US-based company developing IP-protected dietary products and functional foods to support consumers as they manage their health and affect the onset of age-related conditions. Evgen’s Board is led by Barry Clare and the company welcomed Richard Moulson as Chief Financial Officer in January 2017. Dr Huw Jones joined Evgen in October 2020 as Chief Executive Officer.
moneymunch
21/3/2021
10:07
GWP took 20 years and them listing on NASDAQ though...
the stigologist
21/3/2021
09:13
httPs://businesscann.com/worlds-largest-ever-cannabis-deal-sees-uk-firm-gw-pharma-bought-for-7-2bn/ News articles like the above are what keep me from being too impatient - when you have a naturally occurring substance that the market goes crazy for, largely because it suddenly/rapidly recognizes its myriad number of therapeutic capabilities. And then values them accordingly. Well, the rewards are obvious. See the parallels??
bumpa33
Chat Pages: Latest  324  323  322  321  320  319  318  317  316  315  314  313  Older
ADVFN Advertorial
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210514 10:48:34